Skip to main content
ONCO logo
ONCO
(NASDAQ)
Onconetix, Inc.
$0.12-- (--)
Loading... - Market loading

Onconetix (ONCO) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Onconetix, Inc.
ONCONasdaq Stock MarketHealthcareBiotechnology

About Onconetix

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Company Information

CEODavid White
Founded2018
IPO DateFebruary 18, 2022
Employees2
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone513 620 4101
Address
201 East Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States

Corporate Identifiers

CIK0001782107
CUSIP68237Q302
ISINUS68237Q3020
SIC2834

Leadership Team & Key Executives

David Allan White C.A., C.P.A., ICD.D
Chief Executive Officer
Karina M. Fedasz
Interim Chief Financial Officer
Andrew D. Skibo Ph.D.
Global Head of Biologics Operations
Dr. Brian Price Ph.D.
Head of Technology Strategy
Theodore Scott Yoho
Head of Business Development
Dr. Ali I. Fattom Ph.D.
Head of Science and Discovery
Dr. Jay Newmark M.B.A., M.D.
Chief Medical Officer